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Raphael H. Valdiviaa
Department of Molecular Genetics and Microbiology, Center for Microbial Pathogenesis, Duke University, Durham, North Carolina, USAa; Department of Microbiology and
Molecular Genetics, Michigan State University, East Lansing, Michigan, USAb; Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley,
California, USAc
ABSTRACT STING (stimulator of interferon [IFN] genes) initiates type I IFN responses in mammalian cells through the detection
of microbial nucleic acids. The membrane-bound obligate intracellular bacterium Chlamydia trachomatis induces a STING-
dependent type I IFN response in infected cells, yet the IFN-inducing ligand remains unknown. In this report, we provide evi-
dence that Chlamydia synthesizes cyclic di-AMP (c-di-AMP), a nucleic acid metabolite not previously identified in Gram-
negative bacteria, and that this metabolite is a prominent ligand for STING-mediated activation of IFN responses during
infection. We used primary mouse lung fibroblasts and HEK293T cells to compare IFN- responses to Chlamydia infection,
c-di-AMP, and other type I IFN-inducing stimuli. Chlamydia infection and c-di-AMP treatment induced type I IFN responses in
cells expressing STING but not in cells expressing STING variants that cannot sense cyclic dinucleotides but still respond to cy-
toplasmic DNA. The failure to induce a type I IFN response to Chlamydia and c-di-AMP correlated with the inability of STING
to relocalize from the endoplasmic reticulum to cytoplasmic punctate signaling complexes required for IFN activation. We con-
clude that Chlamydia induces STING-mediated IFN responses through the detection of c-di-AMP in the host cell cytosol and
propose that c-di-AMP is the ligand predominantly responsible for inducing such a response in Chlamydia-infected cells.
IMPORTANCE This study shows that the Gram-negative obligate pathogen Chlamydia trachomatis, a major cause of pelvic in-
flammatory disease and infertility, synthesizes cyclic di-AMP (c-di-AMP), a nucleic acid metabolite that thus far has been de-
scribed only in Gram-positive bacteria. We further provide evidence that the host cell employs an endoplasmic reticulum (ER)-
localized cytoplasmic sensor, STING (stimulator of interferon [IFN] genes), to detect c-di-AMP synthesized by Chlamydia and
induce a protective IFN response. This detection occurs even though Chlamydia is confined to a membrane-bound vacuole. This
raises the possibility that the ER, an organelle that innervates the entire cytoplasm, is equipped with pattern recognition recep-
tors that can directly survey membrane-bound pathogen-containing vacuoles for leaking microbe-specific metabolites to mount
type I IFN responses required to control microbial infections.
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The obligate intracellular pathogen Chlamydia trachomatis isthemost common sexually transmitted bacterial infection and
the leading cause of preventable blindness worldwide. As a conse-
quence of inflammatory damage from repeated and chronic infec-
tions, severe sequelae can occur such as blinding trachoma, pelvic
inflammatory disease, and infertility (1). Elementary bodies (EB),
the infective formofC. trachomatis, attach to and invade epithelial
cells of the conjunctiva and urogenital tract. After entry, the EB
form transitions to the metabolically active reticulate body (RB),
which replicates within amembrane-bound compartment known
as the inclusion. Midway through the Chlamydia infectious cycle,
RB replication becomes asynchronous, generating both RBs and
EBs (2). EBs exit the cell through either lysis of the host cell or
extrusion of the inclusion to infect neighboring cells (3).
Microbial compounds are recognized by surface-exposed and
intracellular immune receptors, leading to the transcriptional ac-
tivation of cytokines and other host defense genes (4). For in-
stance, type I interferons (IFNs) are secreted in response to diverse
viral and bacterial infections (5, 6). Although the antiviral prop-
erties of IFNs are fairly well characterized, the role that these cy-
tokines play in controlling bacterial infections is less well under-
stood, as they can both block and enhance pathogen replication in
vivo (7–11). All cell types can initiate type I IFN responses through
Toll-like receptor (TLR)-dependent and TLR-independent path-
ways. TLR-independent pathways include cytosolic sensing ofmi-
crobial ligands such as cell wall fragments through NF-B-
activating NOD1/NOD2 receptors (12) and double-stranded
DNA (dsDNA) or dsRNA-like molecules through the action of
RNA polymerase III (13), RIG-I (14),MAVS (15), cGAS (16), and
STING (stimulator of IFN genes; also known as Eris, MITA, and
MPYS) (17–20).
C. trachomatis induces type I IFN responses in a variety of cell
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types. Previous work has provided evidence for (21) and against
(22) a role for TLRs in the regulation of type I IFN responses to
Chlamydia infection. Prantner and colleagues identified STING, a
key mediator of responses to cytosolic DNA, RNA, cyclic dinucle-
otides, and membrane fusion (19, 23–25), as important for the
induction of type I IFNs in Chlamydia-infected cells (22). STING
is an endoplasmic reticulum (ER) integralmembrane protein (26)
that, upon exposure to cytoplasmic dsDNA, is redistributed to
p62-positive punctate structures in the cytoplasm (“sequesto-
somes”) that colocalize with autophagy-related proteins (26, 27).
Unlike sensing of dsDNA in the cytoplasm, which requires addi-
tional cofactors, STING can directly bind to bacterium-specific
cyclic dinucleotides (24) and trigger potent type I IFN responses to
intracellular pathogens such as Listeria monocytogenes and Legio-
nella pneumophila (28–30).
Diadenylate cyclases (DACs) are found in a wide variety of
Gram-positive bacteria and are required for the synthesis of cyclic
di-AMP (c-di-AMP) (31). A related cyclic dinucleotide, c-di-
GMP, is a well-established regulator of bacterial virulence, biofilm
formation, motility, and gene expression (32). In contrast, the
function of c-di-AMP is less well characterized. The DNA
integrity-scanning proteinDisA, found inBacillus subtilis, synthe-
sizes c-di-AMP in the presence of intact DNA to activate sporula-
tion genes (33, 34). In addition, cell wall homeostasis is regulated
by c-di-AMP, as elevated levels of this cyclic dinucleotide com-
pensate for a lack of teichoic acids in Staphylococcus aureus (35),
and enhances resistance to -lactam antibiotics in B. subtilis by
increasing peptidoglycan cross-linking (36). Overall, c-di-AMP
appears to be important inGram-positive bacteria for adaptations
to membrane and cell wall stress.
In this study, we provide the first experimental evidence that
C. trachomatis, a Gram-negative bacterium, synthesizes c-di-AMP
during the late stages of infection and that the CT012 gene func-
tions as a DAC. Furthermore, we show that c-di-AMP is largely
responsible for driving type I IFN responses in Chlamydia-
infected cells and that the sensing of this metabolite is mediated at
the ER by the immune sensor STING.
RESULTS
The Chlamydia gene dacA (CT012) encodes a DAC. The host
cytosolic sensor STING could directly and indirectly sense RNA,
DNA, and cyclic dinucleotides (17, 19, 24, 26, 37–41) to mediate
IFN responses during Chlamydia infection (22, 42–47). Given re-
cent evidence that STING senses cyclic dinucleotides directly (24),
we were intrigued by the presence in C. trachomatis of an open
reading frame (CT012) with sequence homology to the B. subtilis
DAC domain-containing protein YbbP and the L. monocytogenes
DAC DacA (Fig. 1A and B). B. subtilis contains three DAC
domain-containing proteins (Fig. 1A), including the DNA
integrity-scanning proteinDisA (34).C. trachomatisCT012has an
N-terminal transmembrane (TM) domain and a putative catalytic
domain with the conserved amino acids Asp-Gly-Ala (DGA) and
Arg-His-Arg (RHR) found in bacterial DACs (Fig. 1B). On the
basis of these similarities, we hypothesized thatChlamydia synthe-
sizes c-di-AMP and that IFN responses may be mediated through
the sensing of this metabolite in the host cytosol.
We first determined if the putativeChlamydiaDAC (CT012) is
capable of synthesizing c-di-AMP. We expressed various
hexahistidine-tagged forms of CT012 in Escherichia coli, which
lacks any known DACs, including full-length CT012, a version
lacking the TMdomain (TM) and a TMCT012 with the aspar-
tate in the DGA motif mutated to asparagine (Fig. 1C). Using
ultraperformance liquid chromatography-tandem mass spec-
trometry (UPLC-MS/MS), we detected high levels of c-di-AMP in
E. coli strains expressing either full-length or TMCT012 but only
minor amounts in strains expressing a D164N mutant form of
TMCT012 (Fig. 1D). Expression levels of these TM variants of
CT012 proteins were found to be similar by Western blotting
(Fig. 1D). It is possible that, on a per-protein basis, full-length
DacA is more active than the truncated forms. However, without
FIG 1 TheC. trachomatis proteinDacA (CT102) displays DAC activity. (A)Domain architecture ofB. subtilisDACdomain-containing proteins DisA, YojJ, and
Ybbp with L. monocytogenes DacA and the C. trachomatis putative DAC CT012. HhH1, helix-hairpin-helix motif; TM, three TM domains). (B) Amino acid
sequence alignment of conserved domain regions of C. trachomatis DacA and DACs from c-di-AMP-producing bacteria with conserved residues critical for
c-di-AMP synthesis indicated (asterisks). One hundred percent similarity, black; 80 to 100% similarity, dark gray; 60 to 80% similarity, light gray; 60%
similarity, white. (C) Schematics of threeC. trachomatisDacA recombinant variants used in this work tomonitor c-di-AMP synthesis in E. coli. (D) UPLC-based
quantification of c-di-AMP levels from nucleotide extracts of E. coli expressing full-length ChlamydiaDacA, the DAC domain of DacA, or DacA with a D164N
point mutation in the putative active site with corresponding immunoblot assays showing levels of DacA in soluble protein extracts. The data shown are means
 standard deviations of two independent experiments. Commercial c-di-AMP (Biolog) was used for calibration and quantification of nucleotide extracts.
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ameans to assess properly folded protein in this E. coli overexpres-
sion system, we cannot make any firm statement to that effect.
Nonetheless, these findings indicate that CT012 has DAC activity
and thus we have renamed the gene encoding this protein dacA.
C. trachomatis synthesizes c-di-AMP during infection. To
determine if Chlamydia synthesizes c-di-AMP during infection,
nucleic acids were isolated from HeLa cells infected with C. tra-
chomatis at various time points postinfection and analyzed by
UPLC-MS/MSunder conditions optimized for the separation and
detection of cyclic dinucleotides. Synthetic c-di-AMP was used as
the standard for the identification and quantification of c-di-AMP
within extracts. c-di-AMP was detected in Chlamydia-infected
cells as early as 12 h postinfection (hpi) and continued to increase
throughout the infectious cycle (Fig. 2A). Peak c-di-AMP levels
were observed at 36 hpi. It is unlikely that Chlamydia synthesizes
c-di-GMP, a metabolite known to induce IFN responses, as c-di-
GMP was undetectable in infected samples (data not shown) and
Chlamydia lacks any proteins with GGDEF or EAL domains. We
also generated DacA-specific antiserum that detected two immu-
noreactive bands consistent with the predicted DacA monomer
and dimer molecular weights (Fig. 2A), consistent with recent
observations with B. subtilis YbbP/CdaA (48), the closest homo-
logue of Chlamydia DacA. The levels of DacA protein expression
correlated with the abundance of c-di-AMP during infection and
type I IFN responses in Chlamydia-infected murine embryonic
fibroblasts (MEFs) (Fig. 2B).
We next compared the levels of c-di-AMP in infectious EBs
with those in replicative RBs. Nucleic acids were extracted from
density gradient-purified EBs and RBs and analyzed by UPLC-
MS/MS. c-di-AMP was detected in EBs but not in RBs (Fig. 2C).
The purity of gradient-purified EBs and RBs was assessed by their
morphology (data not shown). These results are consistent with
DNA microarray results (49) and proteomic data sets showing
that DacA is expressed in EBs but not in RBs (50). EB lysates
treated with snake venom phosphodiesterase (SVP) lost the peak
corresponding to c-di-AMP, indicating that the peaks detected
contain 3=-5= phosphate linkages. Overall, these results indicate
that Chlamydia synthesizes c-di-AMP during infection and that
this metabolite accumulates primarily within EBs.
STING is required for type I IFN responses toC. trachomatis
and cell autonomous control of bacterial replication.Chlamydia
induces type I IFN responses in a variety of cell types, and evidence
from RNA interference-mediated gene silencing suggests that this
response requires STING (22).We extended these findings to pri-
mary cells derived from STING-deficient animals. First, we deter-
mined that primary mouse lung fibroblasts (MLFs) induced sig-
nificant levels of type I IFN as detected by the induction of
luciferase expression in a reporter cell line containing an ISRE-luc
transgene and by measuring secreted IFN- by enzyme-linked
immunosorbent assay (ELISA) (Fig. 2B and 3A and B). These
MLFs also induced type I IFN in response to the delivery of the
dsRNA analogue poly(I-C), dsDNA, and c-di-AMP to the cytosol
(Fig. 3A), indicating that the sensing machinery for nucleic acids
in the cytoplasm is intact in these cells.
By forward genetic screening of N-ethyl-N-nitrosourea-
mutagenized C57BL/6 mice, Sauer and colleagues identified a
mouse strain with impaired type I IFN responses to L. monocyto-
genes (51). The loss of responsiveness in these mice (Goldenticket)
was due to a destabilizing point mutation in STING. We isolated
fibroblasts from wild-type and Goldenticket mouse lungs and
FIG 2 c-di-AMP is present in nucleic acid extracts from cells infected with
C. trachomatis. (A) c-di-AMP levels in extracts of HeLa cells infected with
C. trachomatis were quantified by UPLC at the indicated time points. The
corresponding immunoblot shows Chlamydia DacA and MOMP expression
levels. Asterisks indicate monomeric (*) and dimeric (**) forms of DacA. (B)
MEFs induce type I IFN in response to Chlamydia infection. MEFs stably
expressing an ISRE fused to a luciferase reporter genewere infectedwithC. tra-
chomatis for the indicated times and lysed, and luciferase levels were assessed
by an enzymatic assay. AU, arbitrary units. (C) c-di-AMP levels in lysates of
density gradient-purified RBs and EBs. The signal for c-di-AMP was sensitive
to SVP. The data shown are means  standard deviations of two technical
replicates.
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tested their abilities to respond to Chlamydia infection. Gold-
enticket MLFs were unable to mount a type I IFN response to
C. trachomatis at increasing multiplicities of infection (MOIs)
(Fig. 3B), confirming STING’s essential role in mediating type I
IFN responses toChlamydia. Furthermore, we observed that wild-
type MLFs produced fewer Chlamydia infectious units than did
GoldenticketMLFs (Fig. 3C), indicating a protective role for type I
IFNs in cell autonomous control of Chlamydia infection, as has
been previously reported (46).
Chlamydia-induced type I IFN responses are mediated pre-
dominantly by c-di-AMP. Because type I IFN responses to Chla-
mydia require STING (22), we postulated that sensing of Chla-
mydia is likely due to the detection of bacterial dsDNA, RNA, or
c-di-AMP in the host cytoplasm. Burdette and colleagues recently
identified a mutation (R231A) that renders STING incapable of
responding to cyclic dinucleotides while retaining the ability to
respond to dsDNA (24). To test the contribution of c-di-AMP to
the triggering of type I IFN responses duringChlamydia infection,
we stably expressed wild-type STING-hemagglutinin (HA) or
STINGR231A-HA by retrovirus-mediated transduction of expres-
sion constructs intoHEK293T cells. HEK293T cells do not express
detectable levels of STING (24) or TLRs (52), and exogenously
expressed STING is sufficient to recapitulate IFN responses to
cyclic dinucleotides but not dsDNA (24) (Fig. 4A). Chlamydia
infection triggered the expression of type I IFNs in HEK293T cells
expressing wild-type STING-HA but not c-di-AMP-blind
STINGR231A-HA (Fig. 4B). At high MOIs, we observed increased
cytopathic effects (data not shown), which likely explains the ap-
parent decrease in type I IFN responses. Overall, these findings
indicate that c-di-AMP sensing during Chlamydia infection is a
relevant inducer of IFN responses.
We could not directly address the role ofChlamydiaDNAsens-
ing in the induction of IFN responses in these cells because
HEK293T cells do not express cytoplasmic dsDNA sensors that
signal through STING (16, 24, 53). To address this problem, we
complemented T-antigen/telomerase-immortalized (54) Gold-
enticket MLFs with a wild-type STING-HA or STINGR231A-HA
expression construct and assessed the expression of type I IFNs
during infection. We observed significant variability in IFN re-
sponses among batches of primary cells (data not shown) and thus
chose to complement a clonal, immortalized Goldenticket MLF
linewith STING-HA constructs tominimize cell-to-cell variation.
STINGR231A-HA MLFs secreted IFN in response to transfected
cytosolic poly(I-C) and dsDNA (Fig. 4C) but did not respond to
c-di-AMP (Fig. 4C) or C. trachomatis infection (Fig. 4D; see
Fig. S2 in the supplemental material), indicating that c-di-AMP is
the predominant Chlamydia-derived molecule recognized by
the host cytoplasmic sensors in fibroblasts. While the expression
of wild-type STING-HA and STINGR231A-HA, as assessed by
immunoblotting, was comparable among HEK293T cells,
STINGR231A-HA expression was slightly elevated compared to
that of wild-type STING-HA in Goldenticket MLFs (Fig. 4E),
which likely accounts for the observed elevated type I IFN re-
sponses to poly(I-C) and dsDNA (Fig. 4C). Finally, consistent
with the role of type I IFNs in cell autonomous control of intra-
cellular pathogens (46), C. trachomatis replication was signifi-
cantly enhanced in Goldenticket MLFs expressing
STINGR231A-HA compared to that in MLFs expressing wild-type
STING-HA (Fig. 4F).
FIG 3 STING is required for the expression of type I IFN in mouse MLFs
during C. trachomatis infection. (A) MLFs induce type I IFNs in response to
various microbial-signal-like signals. MLFs were transfected with dsDNA or
poly(I-C), loaded with c-di-AMP by digitonin permeabilization, or infected
with C. trachomatis for 30 h. Cells treated with transfection (LuoVec and
Xtreme9) or cell permeabilization reagents alone were included as controls.
Levels of secreted type I IFNs in cell supernatants were assessed with a reporter
cell line stably expressing an ISRE fused to a luciferase reporter gene and
monitoring of luciferase enzymatic activity. AU, arbitrary units. (B) IFN-
responses to C. trachomatis infection requires STING. MLFs from wild-type
(WT) and STINGGt/Gt (Goldenticket) mice were infected withC. trachomatis at
the indicated MOIs for 30 h, and the levels of IFN- in cell supernatants was
determined by ELISA. (C) STING-deficient (STINGGt/Gt)MLFs are permissive
for C. trachomatis replication. Wild-type and STINGGt/Gt MLFs were infected
withC. trachomatis at the indicatedMOIs, and the yield of infectious units was
determined at 36 hpi. Fold change represents the ratio of the number of infec-
tious units/l observed inGoldenticketfibroblasts to that observed inwild-type
fibroblasts. All data are means  standard deviations of three independent
samples , P  0.001; , P 0.001 (one-way analysis of variance and
Newman-Keuls multiple-comparison test).
Barker et al.
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FIG 4 c-di-AMP is themain ligand responsible forChlamydia-mediated type I IFN responses. (A and B) STING expression is sufficient for the induction of IFN
responses during C. trachomatis infection. HEK293T cells stably expressing an ISRE-luciferase reporter were transduced with a wild-type STING-HA (black) or
a STINGR231A-HA (gray) retroviral vector and treated with dsDNA or c-di-AMP (A) or infected with C. trachomatis for 30 h at the MOIs indicated (B)., P
0.05; **, P 0.001; ***, P 0.001 (one-way analysis of variance and Newman-Keuls multiple-comparison test). Cells expressing mutant STINGR231A cannot
induce type I IFNs in response to c-di-AMP. AU, arbitrary units. (C to F)MLFs expressing STING variants that cannot signal in response to cyclic dinucleotides
fail to induce type I IFNs during C. trachomatis infection. Goldenticket MLFs transduced with a wild-type STING-HA (black) or a STINGR231A-HA (gray)
construct were treated with poly(I-C), dsDNA, or c-di-AMP (C) or infected with C. trachomatis for 30 h (D). *, P  0.05 (one-way analysis of variance and
Newman-Keuls multiple-comparison test). Supernatants were tested for IFN- levels by ELISA. Fold changes represent the ratios of total IFN- detected by
ELISA (in pg/ml) in cells treated with stimulants to that in untreated cells (C) and that in infected cells to that in uninfected cells (D). (E) Immunoblot analysis
with anti-HA (STING) antibody of protein lysates from HEK293T cells and GoldenticketMLFs expressing various STING constructs indicates that comparable
levels of STINGwere expressed in these cell lines. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and actin served as loading controls.WT, wild type. (F)
GoldenticketMLFs expressingwild-type STING-HA (black) or STINGR231A-HAwere infectedwithC. trachomatis, and infectious units were assessed as described
in the legend to Fig. 3C. Note that Goldenticket MLF expressing the STING variant that cannot recognize ci-di-AMP did not induce IFN- and control
C. trachomatis replication. *, P 0.05; **, P 0.05; ***, P 0.001 (one-way analysis of variance and Newman-Keuls multiple-comparison test). Fold changes
represent the ratios of infectious units/l observed in Goldenticket MLF complemented with STING-HAR231A-HA to those in wild-type STING-HA. The data
shown are means standard deviations of three independent samples.
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STING translocation from the ER to cytoplasmic signaling
complexes upon c-di-AMP treatment correlates with the onset
of type I IFN responses. Upon the recognition of dsDNA in the
cytoplasm, STING is redistributed from its steady-state localiza-
tion at the ER to the Golgi apparatus and p62/SQSTSM-
containing cytoplasmic structures (26). Exit from the ER is re-
quired for type I IFN activation in response to dsDNA (17),
leading to the recruitment of serine/threonine-protein Tank-
binding kinase 1 (TBK1), which phosphorylates the transcrip-
tional factor IRF-3 (55). We tested if c-di-AMP is sufficient to
mediate the relocalization of STING. At steady state, HA-tagged
wild-type STING and STINGR231A localized to the ER-like struc-
tures in MLFs (see Fig. 6A). Goldenticket MLFs expressing HA-
tagged wild-type STING, but not MLFs expressing STINGR231A,
relocalized from the ER to punctate structures as early as 30 min
posttreatment with c-di-AMP (Fig. 5). Although STINGR231A
variants bind cyclic dinucleotides (24), we failed to see any STING
translocation at the time points examined. In contrast, wild-type
STING and STINGR231A were readily translocated to p62/
SQSTSM-positive puncta upon transfection with dsDNA but not
poly(I-C) (Fig. 6B andC; see Fig. S3 in the supplementalmaterial).
Neither c-di-AMP treatment (Fig. 6D) nor C. trachomatis infec-
tion (Fig. 6E) induced the translocation of STINGR231A. The per-
centages of cells containing STING-positive cytoplasmic punctate
structures under all of the conditions tested are shown in Fig. 6F.
Overall, these findings strongly suggest that c-di-AMP is the
most prominent microbial ligand driving type I IFN responses
during Chlamydia infection.
DISCUSSION
The Chlamydia-derived ligand(s) driving type I IFN responses
and the corresponding sensing mechanism(s) are unclear. In this
study, we provide evidence that Chlamydia synthesizes c-di-AMP
and that this metabolite is a prominent driver of Chlamydia-
induced IFN responses. To our knowledge, C. trachomatis is the
first Gram-negative pathogen shown to synthesize c-di-AMP.
Vibrio cholerae synthesizes a hybrid cyclic di-AMP-GMPmolecule
(56) via a protein lacking a canonical DAC domain, but whether
this nucleic acid can induce IFN responses during infection is not
known.
The role type I IFNs play in the control ofChlamydia infections
in vivo is unclear. Mice lacking the type I IFN receptor gene (IF-
NAR/) cleared Chlamydia muridarum infections earlier and
displayed reduced pathology in the oviducts (8), suggesting a det-
rimental role for type I IFNs in the outcome of genital tract infec-
tions with C. muridarum. However, type I IFNs can also induce
cell autonomous defense mechanism with antichlamydial activi-
ties (46).
Both murine and human cell lines sense Chlamydia infections
and mount type I IFN responses (45, 58–61). Some studies have
implicated TLR3 in Chlamydia-mediated IFN responses in mu-
rine oviduct epithelial cells (21, 62), while others point to a role for
STING in human cells (22). Here we provide genetic evidence
supporting a prominent role for STING in the sensing of Chla-
mydia ligands by murine cells. MLFs derived from STING-
deficient (Goldenticket) mice did not induce type I IFNs in re-
sponse to C. trachomatis infection (Fig. 3B). Importantly, this
defect in IFN expression by Goldenticket MLFs can be comple-
mented with a wild-type copy of STING but not with a mutant
form of STING (STINGR231A) that binds cyclic dinucleotides but
cannot signal in response to them (24) (Fig. 4D). Because
STINGR231A can still initiate IFN expression in response to cyto-
plasmic DNA, we conclude that chlamydial dsDNA in the cyto-
plasm is unlikely to be amajor contributor to type I IFN responses
during Chlamydia infection. A recent study suggested that the
dsDNA sensor DDX41 (40) can also directly sense cyclic dinucle-
otides and requires STING as an adaptor protein (63). Whether
sensing of c-di-AMP occurs directly through DDX41 or STING,
the lack of IFN responses in cells expressing a STING variant blind
to cyclic dinucleotide-dependent signaling argues that c-di-AMP,
and not dsDNA, is the major ligand driving Chlamydia IFN re-
sponses. Similarly, Chlamydia-derived RNAs are unlikely to be a
major inducer of IFN, as the expression of IFN- in Chlamydia-
infected cells is RIG-I and MAVS independent (22).
Unlike the cytosolic pathogen L. monocytogenes (64), where
secreted metabolites are directly accessible to immune sensors in
the cytoplasm, Chlamydia is surrounded by a membrane vacuole
that is impermeable to small charged molecules 500 Da in size
FIG 5 STING translocates to cytoplasmic structures in response to c-di-
AMP. Goldenticket MLFs transduced with wild-type STING-HA (top) or
STINGR231A-HA (bottom) were treated with c-di-AMP for the indicated
times. Cells were immunostainedwith anti-HA (STING) antibody and imaged
by epifluorescence microscopy.
Barker et al.
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(65). This permeability barrier should limit the detection of chla-
mydial metabolites to microbial pattern recognition receptors.
However, the inclusion is intimately associated with ER mem-
branes, which has been interpreted as a pathogen-mediated pro-
cess evolved to acquire lipids from the host (66–70). An alternative
interpretation is that cells envelope large, abnormal vacuolar
structures with ERmembranes to increase the chance that sensors
like STING can encountermicrobe-derived compounds. In such a
scenario, STING in the ER, an organelle that innervates the entire
cytoplasm, has a greater likelihood of sensing chlamydial c-di-
AMP and translocating to signaling platforms together with TBK1
and IRF3, as previously shown (29, 41, 71) (Fig. 7).
Upon sensing cytoplasmic dsDNA, STING relocalizes from the
ER to the Golgi apparatus and cytoplasmic p62/SQSTSM-positive
puncta (26). STING transport out of the ER upon the sensing of
dsDNA is critical to the initiation of type I IFN responses (17).
This intracellular transport event also occurs in response to cyclic
dinucleotides, even in HEK293T cells, where cytoplasmic dsDNA
sensors are not expressed (Fig. 4A) (24), and is important for
immune signaling, as type I IFN induction in response to c-di-
AMP is blocked by the fungalmetabolite brefeldinA (unpublished
data), an inhibitor of ER-to-Golgi apparatus transport (17). The
molecular mechanisms regulating STING relocalization to cyto-
plasmic signaling complexes are unknown. Autophagy-related
proteins have been implicated in the turnover of STING-positive
signaling complexes, as Atg9a knockout cells show enhanced ac-
cumulation of STING and TBK1 in punctate structures and in-
creased IFN- production (26). Autophagy markers such as LC3
and Atg9a also colocalize with STING, yet STING-positive struc-
tures lack double-membrane-bound morphological characteris-
tics of autophagosomes (26).
Unlike c-di-GMP,which haswell-defined roles in bacterial vir-
ulence, including motility, biofilm formation, and virulence gene
expression (72), the function of c-di-AMP in bacteria is less well
understood. c-di-AMPwas first identified in B. subtilis as a second
messenger involved in signaling DNA integrity to regulate sporu-
lation (33, 34). In S. aureus, c-di-AMP regulates peptidoglycan
cross-linking and bacterial survival in the absence of lipoteichoic
acids (35). Chlamydia contains a single gene for the synthesis of
c-di-AMP, dacA, and a single putative phosphodiesterase gene
with homology to proteins that cleave or inactivate c-di-AMP
(73). While the role of c-di-AMP in C. trachomatis is unknown,
the timing of c-di-AMP detection during infectionmimics that of
conversion of RB to EB forms (~15 hpi) and a quantitative pro-
FIG 6 (A) A STING variant (STINGR231A) that does not signal in response to c-di-AMP fails to translocate to cytoplasmic complexes uponChlamydia infection.
Immortalized GoldenticketMLFs expressing a wild-type STING-HA or a cyclic dinucleotide-blind STINGR231A-HA construct were treated with digitonin alone
(A), transfected with the dsRNA analogue poly(I-C) (B) or dsDNA (C) for 24 h, loaded with c-di-AMP after digitonin permeabilization for 8 h (D), or infected
with C. trachomatis for 30 h (E). Cells were fixed and stained with anti-HA (STING) antibody and imaged by confocal laser scanning microscopy. Note that
STINGR231A cannot translocate to cytoplasmic punctate structures (arrows) in response toC. trachomatis infection or c-di-AMP stimulation but is responsive to
dsDNA treatment. (F)Quantification of the percentage of cells displaying STING in cytoplasmic puncta after treatmentwith various inducers of type I IFNs. Cells
displaying puncta (arrows) were scored as positive for STING translocation (n 150).
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teomic study identified DacA only in purified EBs and not RBs
(50). Given the prominent role of cyclic dinucleotides like c-di-
GMP in the regulation of protein function, gene expression, and
the posttranscriptional regulation of mRNAs, we speculate that
c-di-AMP may have similar regulatory functions, especially dur-
ing the transition frommetabolically active RBs to infectious EBs.
As in other bacterial systems (29, 48), c-di-AMP may turn out
to be an essential molecule in Chlamydia. Indeed, in a recent
screen for essentialChlamydia genes, we have been unable to iden-
tify loss-of-function mutations in dacA (unpublished data). It is
apt that an immune sensing mechanism would have evolved to
detect conserved, essential bacterial metabolites.
MATERIALS AND METHODS
Organisms and cell culture. C. trachomatis serovar LGV-L2 (strain 434/
Bu) was grown in HeLa cells, MLFs, or HEK293T cells maintained in
Dulbecco’s modified Eagle’s medium plus 10% fetal bovine serum (FBS).
Primary LF isolation. Primary lung fibroblasts (LFs) were isolated
from Sting-deficient Goldenticket (51) and parental wild-type C57BL/6
mouse lungs. Briefly, lung tissues were minced and transferred into a
sterile beaker containing a stir bar and 10 ml of Dulbecco’s modified
Eagle’s medium (DMEM)with 0.14Wunsch unit/ml Liberase Blendzyme
3 (Roche) and 1 antibiotic-antimycotic (penicillin-streptomycin and
amphotericin B; Gibco). Samples were incubated at 37°C with slow stir-
ring for 60min, washed three times with 10ml DMEMwith 15% FBS and
1 antibiotic-antimycotic. Tubes were spun at 524  g in a swinging-
bucket centrifuge for 5 min, and the cell pellet was resuspended twice in
10 ml DMEM–15% FBS–1 antibiotic-antimycotic and transferred to a
10-cm dish. Cells were incubated at 37°C in a humidified 5% CO2 atmo-
sphere. Primary LFs were stored in frozen aliquots or immortalized by
retroviral delivery of simian virus 40 T antigen and human telomerase
reverse transcriptase as previously described (54).
Plasmid constructs and virus production. STING expression con-
structs (24)were delivered intoHEK293T cells and immortalized LFs, and
positive transductants were sorted on a FACSVantage sorter (BD) on the
basis of the levels of enhanced green fluorescent protein (EGFP) expres-
sion. For stable expression of STING-HA, viruses were generated in 293T
cells seeded into 10-cm dishes at 1  106 cells/dish and transfected with
STING-HA retroviral constructs and packaging plasmid pCL10A1 at a 1:1
ratio with FuGENE6 (Promega). At 48 h posttransfection, the cell super-
natant was collected, filtered over 0.44-m filters (Pall), and added to
immortalized Goldenticket LFs. Stable transductants were sorted on the
basis of EGFP expression levels.
CT012 (dacA) andCT102 lacking the TMdomain (minus amino acids
1 to 86)was inserted into pET28a for overexpression in BL21-CodonPlus-
RIL cells (Stratagene). Mutations in the putative active site of CT012 were
generated with the QuikChange site-directed mutagenesis kit (Strat-
agene) according to the manufacturer’s guidelines.
Generationof anti-DacAantibodies.Hexahistidine-taggedDacAwas
generated by cloning a fragment of CT012 lacking the TM domain into
pET28a. Recombinant protein was produced in BL21-CodonPlus-RIL
cells (Stratagene) and purified by affinity chromatography on nickel-
charged resin (Qiagen). Purified, recombinant DAC was used to immu-
nize a rabbit. The antiserumwas precleared of cross-reactive antibodies by
incubation with crude HeLa cell lysate at 4°C for 2 h prior to use in
immunoblotting.
Analysis of DacA expression. HeLa cell monolayers were infected
with serovar LGV-L2 at an MOI of ~1. Infections were synchronized at
4°C, and total protein was collected at 0, 1, 4, 8, 12, 24, and 36 hpi by lysis
in hot sample buffer (50 mM Tris [pH 6.8], 2% SDS, 10% glycerol, 1%
-mercaptoethanol, 0.02% bromophenol blue), followed by sonication.
Proteins were separated by SDS-PAGE and transferred to nitrocellulose
membranes (Bio-Rad). Blots were blocked in 5% nonfat milk diluted in
Tris-buffered saline (0.5MTris, 1.5MNaCl, pH 7.4) with 0.1%Tween 20
(TBST) and incubated overnight with primary anti-Dac antibody diluted
in 5% milk–TBST. The blots were washed in TBST and incubated with a
horseradish peroxidase-linked anti-rabbit secondary antibody (GE
Healthcare). Bound antibodies were detected with the SuperSignal West
Dura detection kit (Thermo).
Cell stimulation. Cells were infected with serovar LGV-L2 for 30 h or
transfected with 250 ng/l poly(I-C)/LyoVec (Invivogene) or 5 g plas-
mid dsDNA (Xtreme 9; Roche) for 24 h. For c-di-AMPdelivery, cells were
incubated with 10 g/ml digitonin (Calbiochem) and 10 M c-di-AMP
(Biolog) in permeabilization buffer (50mMHEPES [pH 7], 100mMKCl,
3 mM MgCl2, 85 mM sucrose, 0.2% bovine serum albumin, 0.1 mM
dithiothreitol, 1 mM ATP, 0.1 mM GTP) for 30 min at 37°C in 5% CO2.
The permeabilization buffer was removed and replaced with DMEM–
FIG 7 Model of activation of STING-dependent IFN- responses in Chlamydia-infected cells. The bacterial metabolite c-di-AMP is synthesized by Chlamydia
and sensed by STING at ERmembranes enveloping the inclusion. STING is transported out of the ER (26) to theGolgi apparatus and eventually to p62/SQSTSM
cytoplasmic complexes (see Fig. S3 in the supplemental material). As previously shown, the recruitment of TBK1 and IRF3 to these signaling platforms leads to
IRF3 phosphorylation and translocation to the nucleus and expression of type I IFN genes (29, 71).
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10% FBS, and cells were incubated at 37°C in 5% CO2 for 8 h. Controls
included digitonin permeabilization without c-di-AMP.
Type I IFN expression. Expression of type IFNs was assessed either
with reporter cell lines or by ELISA. For reporter cell line construction,
lentiviruses containing an IFN-stimulated response element (ISRE)-
luciferase reporter (SABiosciences) was used to stably transduce MEFs.
These cells were seeded into 96-well plates in triplicate, and supernatants
from cells treated with various IFN-inducing stimuli were added. Post-
stimulation, the medium was removed and cells were washed once with
phosphate-buffered saline (PBS). Cells were lysed in 50l of britelite plus
reagent per well (PerkinElmer), and the samples were transferred to a
white OptiPlate (PerkinElmer) for measurement of luminescence on an
EnSpire 2300 Multilabel Plate Reader (PerkinElmer).
For IFN- ELISAs, cells were seeded into 96-well plates in triplicate at
1  104/well. Poststimulation, medium was collected and analyzed for
IFN- levels according to the manufacturer’s protocol (VeriKine Mouse
IFN- ELISA kit; Pestka Biomedical Laboratories). For MLFs expressing
STING-HA constructs, results were normalized to the GFP expression of
adherent cells as measured by an EnSpire 2300 Multilabel Reader
(PerkinElmer).
c-di-AMP extraction. E. coli BL21-CodonPlus-RIL (Stratagene) cells
were used to overexpressChlamydiaDacA constructs. Overnight cultures
were diluted in 100 ml minimal medium and incubated at 37°C for 3 h.
Isopropyl--D-thiogalactopyranoside (IPTG) was added to a final con-
centration of 0.5 mM, and cells were incubated at 37°C for 4 h (OD600 of
0.4). Cultures were spun at 5,100 rpm for 30 min at 4°C, and the bacterial
pellets were resuspended in 250 l extraction buffer (40:40:20 methanol-
acetonitrile-H2O plus 0.1 N formic acid). Samples were incubated at
20°C for 30 min, and then insoluble material was pelleted by centrifu-
gation at 13,000 rpm for 5min at 4°C. A 200-l volume of the supernatant
was collected and neutralizedwithNH4HCO3 (0.6%final concentration).
Samples were stored at80°C until UPLC analysis. For c-di-AMP extrac-
tion from infected cells, HeLa cells were seeded into six-well plates and
infected withC. trachomatis at anMOI of 1. Infections were synchronized
by centrifugation at 3,000 rpm for 30min at 4°C and then transferred to a
37°C 5%CO2humidified incubator. At the indicated time points, infected
cells were harvested and nucleotides were extracted from the pellet as
described above.
UPLC-MS/MS analysis. c-di-AMP was quantified by UPLC-MS/MS
as previously described (74). Immediately before analysis, 100 l of each
sample was centrifuged under a vacuum for 2 h to remove the extraction
buffer and the remaining pellet was then resuspended in 100 l water. A
10-l volume was analyzed on a Quattro Premier XE mass spectrometer
(Waters) coupled with an Acquity Ultra Performance LC system (Waters)
alongside an eight-point standard curve of purified c-di-AMP (Biolog)
ranging from250 to 1.95 nM.The limit of detection of cyclic dinucleotides
was1 nM. c-di-AMP was detected in all infected cell lines.
Isolation of EB and RB forms of Chlamydia. Purification of C. tra-
chomatisEBs andRBswas performedby density gradient centrifugation as
previously described (50). To ensure the purity of serovar LGV-L2, stocks
were plaque purified twice before generating EB and RB forms for c-di-
AMP analysis. For c-di-AMP extraction, final pellets were resuspended in
250 l extraction buffer and processed as described for E. coli.
Inclusion-formingunit assay.Wild-type andGoldenticketMLFswere
seeded at 1 104/well into a 96-well plate. Infections were conducted in
triplicate at various MOIs. At 40 hpi, cells were lysed in H2O and SPG
(3.8 mM KH2PO4, 7.2 mM K2HPO4, 4.9 mM L-glutamic acid, 218 mM
sucrose, pH 7.4) was added to a final concentration of 1. Serial dilutions
were used to infect HeLa cell monolayers for 24 h, at which point, cells
were fixedwithmethanol and processed for immunofluorescencemicros-
copy with anti-major outer membrane protein (anti-MOMP) antibodies.
The number of inclusions per well was determined with a Cellomics High
Content imaging system (Thermo Scientific).
Immunofluorescence assays for STING localization.For routine im-
munofluorescence microscopy, cells were fixed with 3% formaldehyde–
0.025% glutaraldehyde for 20 min, permeabilized with 0.1% Triton
X-100–PBS for 20min, and then blocked with 5% bovine serum albumin
in PBS. The primary antibodies used were rat anti-HA (1:500; Roche) and
rabbit anti-p62/SQSTSM1 (1:1,000; Sigma) antibodies. Primary antibod-
ies diluted in PBS were incubated with permeabilized cells at 4°C for 1 h;
this was followed by staining with fluorophore-conjugated secondary an-
tibodies (Molecular Probes) for an additional 1 h. DNA was stained with
Hoechst (Molecular Probes) at a concentration of 1:10,000 in PBS. Cells
were mounted on slides with Mowiol (Sigma) and stored at 4°C. Cells
were imaged by confocal laser scanning microscopy on a Zeiss 510 in-
verted confocal microscope.
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